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ABSTRACT 
Background: Intrauterine growth restriction (IUGR) is one of the leading causes of 
perinatal mortality and morbidity. Nowadays, this condition is detected in the 3rt and last 
trimester of gestation when the pathology is already established and success of 
therapeutic strategies are limited.    
As the physiopathology of the disease suggests that the problem stems from poor 
placental implantation, it would be quite advantageous to identify women at increased risk 
in the first or second trimester of gestation because it then might be possible to offer 
treatment interventions or at least to establish increased surveillance for high risk 
pregnancies. Maternal levels of pregnancy-associated plasma protein-A (PAPP-A) and 
free β human chorionic gonadotropin (free βhCG) has been shown to be effective in first 
trimester screening for chromosomal abnormalities, primarily trisomies 21, 13 and 18. 
Previous studies evaluating PAPP-A and free βhCG measured in the first trimester in 
relation with IUGR have provided conflicting results. Moreover, it has been suggested that 
black ethnicity is another important predictive factor for fetal growth restriction.  
Objective: To analyse the association between first trimester serum analytes (PAPP-A 
and free βhCG) and ethnicity with Intrauterine Growth Restriction.  
Methods: The study consists in a retrospective cohort, including all singleton 
pregnancies with complete outcome data that had undergone first trimester screening 
(PAPP-A and free βhCG) at 11-13+6weeks of gestation between 1/1/2010 - 31/12/2012 in 
Hospital Universitari Dr Josep Trueta. Biochemical markers are converted to multiples of 
the median (MoMs) and percentiles 5 and 10 are calculated. The association between 
free βhCG and PAPP-A with the incidence of IUGR is evaluated in combination with 
maternal ethnicity. Bivariate and logistic regression analyses are performed to adjust this 
association for co variables. 
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1 INTRODUCTION 
 
1.1 Intrauterine growth restriction (IUGR) 
1.1.1 HISTORY 
The terminology used to describe abnormal fetal growth is inconsistent and 
confusing. The first references carried in medical literature concerning low 
birthweight babies refer to 1919 when “premature” was defined as the newborn 
weighing less than 2.500 gram. Afterwards, in 1961 the World Health Organisation 
(WHO) acknowledged that many babies defined as premature were not born early 
on time but they are newborns with “low weight” at born. The current WHO criteria 
for low birth weight are a weight less than 2,500 g or below the 10th percentile for 
gestational age. (1) 
 
1.1.2 CONCEPT 
Intrauterine growth restriction (IUGR) is defined as an estimated weight below the 
10th percentile for the gestational age. It is a dynamic term that implies a 
pathological process in which one or more factors inhibit the pre-programmed 
genetic growth potential and where Doppler Ultrasound is abnormal (2) 
 
By contrast, the concept of small for gestational age (SGA) is purely statistical and it 
is a static term. Include all newborns which weight is below the 10th percentile 
with normal Doppler Ultrasound (2) 
 
 
 
 
 
 
 
 
 
 
 
This distinction is important because newborns with a prenatal diagnosis of IUGR 
have more perinatal morbidity than neonates who meet the criteria for diagnosis of 
SGA, but have an otherwise healthy in-utero environment.(2) IUGR will be the base 
of this study. 
Low birth 
weight (<p 10) 
Non pathologic growth 
SGA 
Normal Doppler 
Pathologic growth 
IUGR 
Abnormal Doppler  
80% asymmetric 
 
20% symmetric 
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1.1.3 EPIDEMIOLOGY AND RELEVANCE 
Fetal growth restriction is the second leading cause of perinatal morbidity and 
mortality, followed only by prematurity (3). The prevalence of IUGR is estimated to 
be approximately 5% in the general obstetric population. (4) However, the incidence 
varies depending on the geographic location and the standard growth curves used 
as reference (5) According to the “Instituto Nacional de Estadística” (INE) the 
prevalence of newborns weighing less than 2500g in Spain during 2012 was 7’77% 
–Picture I– Neonates with low birth weight at term have a perinatal mortality rate 
that is 5 to 30 times higher than the ones who are in the 50th percentile. The rate 
increases to 70-100 times higher when the weigh is less than 1500g (5) Infants with 
IUGR are between 1.6 and 12 times more likely to develop a complication (low 
Apgar score, hypoglycemia, hypothermia, apnea, respiratory distress and fetal 
asphyxia) than infants with an adequate ponderal index.(6)  
Moreover, a worse neurological and cognitive development is assumed to them (7). 
 
1.1.4 CLASSIFICATION AND ETIOLOGY 
 According to time of establishment: early (<28th week) or late (>28th week) 
 According to fetal body proportions (8):  
 Symmetric (type I)  20% of IUGR. Growth pattern in which both cranial and 
abdomen perimeters are proportionally decreased and it is caused by an 
alteration in the cellular hyperplasia phase in all fetal organs during the first 
gestational trimester. The main causes are chromosomal aneuploidies and early 
congenital infections. The fetal morbility and mortality rates are higher in this 
type of IUGR. 
 Asymmetric (type II)  70-80% of IUGR. There is a larger decrease in the 
abdomen perimeter than in the cranial one. When there is not an evident 
explanation of this situation (i.e. maternal hypertension, infection, etc) the main 
cause is an uteroplacental vascular insufficiency, and they start to present signs 
of decreased growth in the 3rt gestational trimester. This condition is the main 
objective of the current study.   
                            Etiology of IUGR 
MATERNAL FETAL/PLACENTA 
- Pathologies: chronic hypertension, pre-
gestational diabetes, collagen vascular 
disease (i.e renal disease, Crohn’s 
disease, systemic lupus erythematosus, 
etc.) 
- Teratogens and toxics: anticonvulsants, 
methotrexate, warfarin, alcohol, smoking, 
drugs. 
- Poor maternal weigh gain and nutrition 
- Extreme maternal age (< 16y or > 35y). 
- Uteroplacental vascular insufficiency 
- Congenital infections (TORCH) 
- Aneuploidies (trisomy 21, 13,18 and 
Turner syndrome) 
- Discordant growth in multiple gestation 
- Congenital malformations 
 3 
 
Asymmetric IUGR is classified in 5 grades according to severity of the vascular insufficiency 
evaluated by Doppler ultrasound: 
1) No suggestive signs of placental insufficiency 
2) Moderate increase in  placental resistance without signs of redistribution 
(umbilical artery PI> p95) 
3) Severe increase in placental resistance without signs of redistribution (umbilical 
artery diastolic flow is absent) 
4) Hemodynamic signs of redistribution (cerebral vasodilatation = middle cerebral 
artery PI <p 5) 
5) Severe hemodynamic impairment (umbilical artery reversed flow and / or 
pulsatile umbilical vein and / or with ductus venosus absent or reversed flow) 
 
1.1.5 SCREENING AND DIAGNOSIS 
Screening of Asymmetric RCIU 
No current screening is made for asymmetric RCIU in the first trimester of gestation.  
- History and physical examination The clinical risk of IUGR is already routinely 
estimated by reviewing the medical and obstetric history. Most clinical studies 
demonstrate that techniques such as measuring the symphysis fundal height (SFH) 
alone missed the diagnosis of IUGR almost half the time. (9) 
- Ultrasound biometry in 2nd trimesterIf IUGR is suspected based on risk factors and/or 
clinical assessment, ultrasonography must be performed to assess fetal size and growth; 
it is the “Gold Standard” in the diagnosis of RCIU in the 3rt trimester. The 
measurements most commonly used are the biparietal diameter, head circumference, 
abdominal circumference and femur length. Percentiles have been established for each 
of these parameters, and fetal weight can be estimated. The most sensitive indicator of 
symmetric and asymmetric IUGR is the abdominal circumference, which has a sensitivity 
of over 95 percent if the measurement is below the 2.5th percentile.(10) Accurate dating 
of the pregnancy is essential in the use of any parameter. In the first trimester, the 
crown-rump length (CRL) is used to estimate gestational age. (11) 
- Amniotic fluid  A decreased volume of amniotic fluid is closely associated with IUGR 
as suggests a redistribution of the blood flow by placenta insufficiency. Significant 
morbidity has been found to exist in pregnancies with an amniotic fluid index value of 
less than 5 cm (12). 
- Doppler Ultrasound (Uterine artery, umbilical artery, middle cerebral artery)  The initial 
sign of feto-placental vascular insufficiency is a reduction in end-diastolic flow, reflected 
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by an elevated PI (pulsatility index). The disease may progress to absent end- diastolic 
flow, and finally to reversed end-diastolic. There is a high transplacentary resistance to 
the blood flow and depending on the grade of severity it will be reflected as a decrease, 
absence or reverse of the flow in the end of the diastole, that is to say, a persistence in 
the notch. In the middle cerebral artery there is a decrease of the pulsatibility and 
resistence index as the hypoxia on the fetus causes a redistribution of the blood flow to 
essential organs (brain, heart and adrenal glands). (13) 
The combination of Ultrasound biometries with umbilical and middle cerebral artery Doppler 
in the 2nd trimester provides the best tool to identify small fetuses at risk for adverse 
outcome.  
Neonatal diagnosis 
The definitive diagnosis is made at birth by confirming the real weight and calculating the 
percentile for the age.  
1.1.6 MANAGEMENT AND TREATMENT 
The management of IUGR must be individualized for each patient. The goal is to deliver the 
healthiest possible infant at the optimal time. To achieve this is important to aim that 
continued fetal tests must be performed to monitor fetal well-being (13): 
 Fetal karyotype  In symmetric RCIU with early onset in the 1rst trimester and 
especially in the context of an abnormal fetal anatomical ultrasound examination 
(documentation of fetal anomalies or soft markers associated with aneuploidy). 
 Doppler studies Enables gradation of severity considering the degree of placental 
disease, the level of distribution and the degree of cardiac compromise. 
 Biophysical profile  Method of assessing the presence of fetal asphyxia and/or chronic 
hypoxia. It is based on 5 variables: fetal breathing, fetal movement, fetal muscle tone, 
non-stress fetal heart rate testing and semi-quantive amniotic fluid volume assessment.  
Once the etiology of IUGR has been established, and the well-being of the fetus is 
confirmed, various investigators have evaluated potential treatment modalities in the hope 
of increasing birth weight and extending gestational age. The universally available 
therapeutic options that currently show any promise in affecting outcome are the antenatal 
administration of steroids in preterm pregnancies (before 34 weeks of gestation) and 
delivery at an institution with a neonatal care unit that is able to address the management 
complexities of the IUGR neonate (14). Other treatments have been evaluated in several 
studies such as: Maternal oxygen administration (15), additional nutrient supplement, 
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hospitalization for bedrest (16), calcium channel blockers (17), low dose ASA(18) and 
heparin(19); but only limited data prove their efficacy. 
1.2  Pregnancy-associated plasma protein (PAPP-A) 
1.2.1 STRUCTURE  
PAPP-A is a macromolecular glycoprotein that belongs to the metzincin superfamily of 
metalloproteinases considered as a new family, the pappalysins. The PAPP-A gene is 
located in 9q33.1 human chromosome. 
PAPP-A exists in pregnancy serum as a heterotetrameric 2:2 complex with 2 subunits 
PAPP-A fixed by disulfide bridges to 2 proMBP molecules (proform of eosinophil major 
basic protein). (20) 
The main site of both PAPP-A and proMBP synthesis during pregnancy is the 
syncytiotrophoblast and is present in the maternal circulation soon after implantation and 
increases in concentrations throughout pregnancy (21) They are also present in several 
reproductive and nonreproductive tissue (i.e female reproductive tissue, kidney, colon, bone 
marrow cells, breast and breast carcinoma) although the levels are much lower than in the 
placenta. (20) 
 
1.2.2 FUNCTION 
This enzyme is unique among other multifunctional proteases capable of degrading insulin-
like growth factor-binding protein-4 (IGFBP-4). IGFBP-4 is a specific protein transporter that 
joins IGF-1 and IGF-2 blocking their interactions with cell surface receptors. As PAPP-A 
splits IGFBP-4, low levels of it are associated with higher levels of IGFBP-4 and 
consequently with lower levels of free IGFs. (22) 
The IGFs play a role in the regulation of fetal growth by controlling uptake of glucose and 
amino acids in trophoblast and its important in the autocrine and paracrine control of 
trophoblast invasion of the decidua. (23) 
1.2.3 PAPP-A IN PREGNANCY 
  
Fig 1: Maternal serum levels of PAPP-
A in 8- 15 weeks of pregnancy  
(Comas, Carmen; Rodríguez, M. Angeles; et al. 
Impact of ductus venosus assessment in screening 
Down syndrome. Donald School Journal of Ultrasound 
in Obstetrics & Gynecology . Apr-Jun2009, Vol. 3 
Issue 2, page 12) 
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1.2.4 CLINICAL APPLICATIONS 
Trisomy 21 (Down syndrome) 
Maternal serum levels of PAPP-A in the first trimester were found significantly reduced (< 0, 
4 MoM) when a fetus was affected by Down syndrome (24). In 1995 it was found that 
maternal levels of PAPP-A and free β human corionic gonadotropin (βhCG) used together 
with maternal age had a detection rate of 62% at a false positive rate of 5% (25). Later, in 
1999 it was found that the most effective method of screening for chromosomal 
abnormalities is by a combination of fetal nuchal translucency thickness and maternal 
serum free βhCG and PAPP-A at 10-14 weeks of gestation. The sensitivity of this screening 
test is estimated as high as 90% for detecting trisomy 21, with a false positive rate of 5% 
(26, 27). Actually this screening test is offered to all pregnant women. 
Other clinical utilities have been studied on its predictive value of detecting threatened 
abortion, ectopic gravidity, preeclampsia and diabetic pregnancy all of them with 
discouraging results. (20) 
1.3 β human chorionic gonadotropin (βhCG) 
1.3.1 STRUCTURE 
Human chorionic gonadotropin (hCG) is a glycoproteic hormone that comprise 2 subunits, 
alpha and beta joined non covalently. The alpha subunit is similar in all glycoproteins 
(luteinising hormone-LH, follicle stimulating hormone-FSH and thyroid-stimulating hormone-
TSH). On the other hand, βhCG is the determinant of his specific biological function and is 
produced by the syncytiotrophoblastic cells of the placenta soon after the implantation of 
the fertilized oocyte. (28) 
1.3.2 FUNCTION 
It has numerous functions. The main one is that interacts with luteinizing hormone / 
chroriogonadotropin receptor (LHCG) and promotes maintenance of the corpus luteum 
during the beginnning of pregnancy, whose function is the secretion of hormone 
progesterone during the first trimester. Progesterone enriches uterus with a thick lining of 
blood vessels and capillaries so that it can sustain fetal growth. Levels of hCG can be 
measured in blood or urine. Moreover, it promotes angiogenesis in uterine vasculature and 
promote growth of cytotrophoblast cells and the invasion as occurs in implantation.  
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1.3.3 βhCG IN PREGNANCY 
It is present in maternal circulation immediately after implantation and raises up until 10 
weeks and then declines to constant level from 20 weeks of gestation.  (29) 
hCG levels in weeks of pregnancy: 
 
 
 
 
 
 
1.3.4 CLINICAL APPLICATIONS (28) 
Pregnancy testing: Determining βhCG serum levels can detect levels as low as 5mlU/ml. 
Tumor marker: High levels of βhCG are associated with gestational throphoblastic tumors 
and testicular cancer. 
Ectopic and abortion pregnancy: High levels without evidence of embryo in the uterus by 
ecography. 
Screening of Down Syndrome: Together with levels of PAPPA, mother’s age and nuchal 
translucency are performed at 11-13 weeks gestation and indicates the individual risk. 
Maternal levels of βhCG were found increased (> 2-2,5 MoM) when the fetus was affected 
(25). 
Fertility: As ovulation inductor instead of luteinising hormone (LH) when there are one or 
more ovarian follicles. It occurs in 38-40 hours after hCG injection and IVF (in vitro 
fecundation) can be proceed.  
 
 
 
 
 
 
 
Fig 2: Serum concentration of human chorionic 
gonadotropin (HCG) during pregnancy.  
(Danforth DN.Textbook of Obstetrics and Gynecology. New York, 
Harper & Row, 1971 pag.531) 
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1.4 Justification 
Intrauterine growth restriction is one of the major determinants of perinatal mortality and 
morbidity. Actually, the diagnosis of this condition is made in the 3rt trimester when it is 
already established. Therefore, a major challenge for the modern obstetrics is finding the 
appropriate method that reports us the risk fetuses and consequently perform a closer 
monitoring, as it has been demonstrated that antenatal detection of SGA significantly 
improved outcome (30). In addition, early identification of high risk women might help to 
discriminate between IUGR fetuses from constitutional small-for-gestational-age (SGA) 
fetuses. 
First trimester serum screening is nowadays used as a method of identifying fetuses at 
increased risk of open neural tube defects and chromosomal abnormalities (trisomy 21 and 
18). Over the last years, numerous authors have studied the potential of first and second 
trimester maternal markers screening to identify impaired placental development and 
subsequent pregnancy complications. Several potent predictive markers have been 
studied, such as Doppler measurements, three dimensional ultrasound volume 
measurements and maternal serum markers. However, large and even controversial 
differences in screening performance are reported.  
Previous studies evaluating PAPP-A and free βhCG measured in first trimester in relation to 
IUGR have provided conflicting results. 
Low levels of both markers have constantly been reported to be associated with IUGR (31, 
32, 33, 34, 35, 36, 37, 44 and 45). However, results of low βhCG were usually not 
statistically significant (32, 34, 35 44 and 45) except from two of them who found 
statistically association (31, 37). In contrast, there are other several studies reporting the 
absence of significant association between first trimester free βhCG and PAPP-A levels 
and subsequent IUGR (38, 42, and 43). Low levels of PAPP-A have more constantly been 
reported with IUGR although a clear level of cut-off in the definition of low PAPP-A is not 
determined (32, 33, 34, 35, 37, 44 and 45).  
Moreover, a recent study found a positive association between high levels of βhCG (>90th 
percentile) and IUGR. Furthermore, the same study found a statistically significant 
association between African-American ethnicity and IUGR with a Relative Risk of 2, 7 (1.7-
4.3) and p value= 0.001. (39) 
Other studies have remarked the importance of ethnicity as an important factor to take into 
account at the moment of correcting levels of such markers when calculating the risk of 
trisomy in the first trimester screening. Significant differences were reported in levels 
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between Caucasian, Afro-Caribbean, Asian and Hispanic ethnicities (40, 41). No study has 
yet examined the relationship between markers, ethnicity and the association with 
Intrauterine Growth Restriction. The great cultural diversity is a relatively emerging issue in 
our country and is different from North America, where these studies were performed.  
Moreover, all previous studies remarked (31, 32, 33, 34, 35, 36, and 37) established as 
definition of IUGR the birth weight under the 10th percentile, without discriminating if 
Doppler was normal or pathologic and therefore including SGA fetuses in the study when it 
is not a pathologic condition.   
In summary, previous studies suggest the association between low levels of PAPP-A and 
βhCG in the first trimester with the subsequent emerge of IUGR even though the results still 
show some controversy. As there is a high suspicion that ethnicity is an important factor 
when interpreting the results, this study will observe if there are differences between 
principal ethnicities in our country (Caucasian, Asiatic, Black-African, Maghreb and Others) 
-with normal and low levels of both biomarkers- and the development of IUGR. IUGR will be 
defined with the actual definition and we will focus only on pathologic growth restriction. 
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2. HYPOTESIS AND OBJECTIVES OF THE WORK 
 
OBJECTIVES 
 To analyze if low levels of βhCG in the first trimester screening test are associated 
with intrauterine growth restriction in pregnant woman subdivided according to 
ethnicity (Caucasian, Asiatic, Maghreb, Black-African and others) 
 To analyze whether low levels of PAPP-A in the first trimester screening test are 
associated with intrauterine growth restriction in pregnant woman subdivided 
according to ethnicity (Caucasian, Asiatic, Maghreb, Black-African and others) 
HYPOTHESIS 
 Intrauterine growth restriction depends on low levels of βhCG in the first trimester of 
gestation and ethnicity. 
 Intrauterine growth restriction depends on low levels of PAPP-A in the first trimester 
of gestation and ethnicity. 
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3. MATERIAL AND METHODS 
3.1 Design 
This study is designed as a retrospective cohort study. From a cohort divided in five groups 
(Caucasian, Asiatic, Maghreb, Black-African and others) and each group subdivided in two 
(normal and low levels of PAPP-A or βhCG) we retrospectively compare if they developed 
IUGR or not in the 3rt trimester of gestation. This process will be done for levels of PAPP-A 
and βhCG separately. 
3.2 Population  
The study population include all women with singleton pregnancies who are excluded of 
major fetal abnormalities in the first trimester screening.   
3.3 Inclusion and exclusion criteria (Table 1) 
INCLUSION EXCLUSION 
 
o Singleton pregnancies 
o Complete screening test first trimester 
o Delivery in our center 
o All data registered 
 
o Multiple gestation 
o Chromosomal abnormalities (T21, T18) 
o Preterm deliveries 
o Miscarriage 
o Pregnancies not ended at our center 
o Women with missing values 
 
3.4 Sample 
SAMPLING METHOD 
Consecutive sampling was carried out as women were tested in the first trimester screening 
and then followed if they gave birth to IUGR fetuses or not.  
The study sample will include all women with singleton pregnancies from 1/1/2010 to 
31/12/2012 (3 years) who delivered at Hospital Universitari Dr Josep Trueta and who 
complied for first trimester screening for trisomy 21 and 18 by a combination of fetal nuchal 
translucency thickness and maternal serum free βhCG and PAPP-A at 11-13+6 weeks of 
gestation. In the Hospital Universitari Dr Josep Trueta this screening test is offered to all 
pregnant women since 07/2008 when the “Programa de diagnòstic prenatal d’anomalíes 
congènites fetals a Catalunya” was approved – Annex 1 – 
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POWER AND SAMPLE SIZE 
Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a two-sided test, 160 exposed 
subjects (low levels of markers) and 480 in the non-exposed (not low levels of markers) are 
necessary to recognize as statistically significant a relative risk greater than or equal to 2. A 
proportion in the non-exposed group has been estimated to be 0, 1. It has been anticipated 
a drop-out rate of 5%.  
This is the necessary sample for the bivariable association but, as our study has 5 different 
cohorts depending on the maternal ethnicity   (Caucasian, Asiatic, Maghreb, Black African 
and Others) we will need 160 exposed subjects of each ethnicity but also 480 subjects non 
exposed  of every ethnicity, making a total of  3200 subjects.  
At the Hospital Josep Trueta approximately 2450 children are born each year, and all 
pregnant women are screened in the first trimester. By analyzing the results of the last 3 
years we will manage to have a sample great enough to ensure a statistically obvious 
difference (≈7350 newborns). 
3.5 Variables. Data collection 
EXPOSURE VARIABLES 
 PAPP-A and βhCG  All pregnant women who accept the screening test of the first 
trimester have a blood sample collected in gestational week 11-13+6. Maternal serum 
PAPP-A and βhCG is measured in our centre’s laboratory using DELFIA Xpress time-
resolved fluoroimmunoassay (Perkin- Elmer, Turku, Finland) – Picture II,III –  and an 
ultrasound examination is carried out to measure nuchal thickness (NT) and crown-
rump length (CRL) by a qualified Obstetrician using a Nemio XG TOSHIBA ® 
ultrasound machine. 
The PAPP-A and βhCG measured in absolute concentrations (ng/mL) are converted 
into multiples of the median (MoM) by dividing the absolute concentration with the 
median concentration at the specific gestational age (estimated by CRL in ultrasound 
examination with validated gestational age tables) and corrected for maternal age. The 
transformation of values is crucial as both glycoproteins change their serum levels 
during pregnancy.  
Data regarding the measures of PAPP-A and βhCG will be obtained through the 
LyfeCycle vs 3.2 Database of the Laboratory Department in Hospital Universitary Dr. 
Josep Trueta – Picture IV –, in which all the serum and ultrasound measures used in 
the first trimester screening test for chromosomal abnormalities are registered. 
Information will be downloaded into the Access Office 2007® Microsoft® database. 
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Low PAPP-A and free βhCG will be defined as <10th percentile from MoMs and we will 
calculate also the relative risk for <5th percentile.ç 
 Ethnicity Defined as the human community having racial, religious, linguistic, and 
certain other traits in common. In Hospital Dr Josep Trueta ethnicity is always recorded 
in the first trimester ecography and classified according: Caucasian, Asiatic, Maghreb, 
Black African or Others.  
OUTCOME VARIABLES 
 Intrauterine growth restriction (IUGR)  Criteria for defining IUGR will be the 
recommended by the “Sociedad Española de Ginecología y Obstetricia” which is the 
one used in Hospital Dr Josep Trueta by all Obstetrics. IUGR is diagnosed on the basis 
of 3 criteria:  
1) A decrement of the estimated fetal weight to below the 10th percentile of a standard 
growth curve depending of gestational age, measured by abdominal circumference. 
This estimation is automatically calculated by the “Calculadora gestacional” v2013.1 
Francesc Figueras.  – Picture V– 
2) A Doppler pulsatility index of umbilical artery greater than the 90th percentile of our 
reference curve – Picture VI – 
3) A birthweight below the 10th percentile for the gestational age curve – Picture VII – 
We use these criteria to identify the subgroup of SGA foetuses with true IUGR 
associated with placental dysfunction. Women will be assigned in two groups. Normal 
pregnancy group is defined as those pregnancies in which a life baby was delivered 
after 37 complete gestational weeks with birth weight at or above the 10th percentile for 
gestational age and sex. The IUGR group differs in that the birth weight is below the 
10th percentile; there is a decrement of estimated fetal weight to below the 10th 
percentile and the Doppler pulsatility index of umbilical artery greater than the 90th 
percentile. Database will be obtained from SAP Gui for Windows Database. 
 
COVARIABLES 
 Maternal age  Measured in years at conception (Mean ± SD) 
 Maternal weight  Measured in kilograms (Mean ± SD) 
 Maternal size  Measured in centimetres (Mean ± SD) 
 Smoking Yes/ No 
 Gestational age  Days (Mean ±SD) 
 Maternal diabetes  Yes/ no 
 Parity  Primiparous/ Multiparous 
 Mean CRL at ultrasound  Cm (mean ± SD) 
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4. STATYSTICAL ANALYSIS 
First, a baseline table will be done with the characteristics of the study population with the 
number and percentage of each variable that we have registered. – Table 1 – 
 
Second, a bivariate analysis will be performed using the Chi2 test of association and the 
proportions will be presented by absolute numbers and percentages. Moreover, the 
Relative Risk (RR) will be calculated for each group. The independent variable will always 
consist of two categorical components: the percentile of the marker and ethnicity, and the 
dependent variable is the presence or absence of IUGR diagnosed by the actual criteria. A 
confidence interval of 95% will be assumed and we will consider p value <0, 05 to consider 
that there is a significance difference. – Table 2 and 3 – 
 
Finally, a Poisson regression will be performed in order to add all the co variables that could 
skew the main association we want to analyse. With continuous variables, if we can 
assume a normal distribution, we will estimate the mean and standard deviation and, if we 
cannot assume it we will estimate the median, first and third quartile. For categorical 
variables overall percentages will be estimated. 
 
 All analyses will be performed using Statistical Package for the Social Sciences (SPSS 
Statistics, ver. 18) 
 
5. ETHICAL CONSIDERATIONS 
All women included in the database signed an informed consent so as to perform the first 
trimester screening test – Annex 2 – 
 
The principle of the World Health Association Declaration of Helsinki of Ethical Principles 
for Medical Research Involving Human Subjects (Assamblea General, Fortaleza, Brazil, 
October 2013), will be followed in the current study. 
 
According to “Ley Orgánica 15/1999, 13 de Diciembre,Protección de Datos de Carácter 
Personal”, clinical history information, names and surnames will remain anonymous when 
collecting data from the database and publishing results. 
 
This protocol will be sent to the CEIC Department (Comitè Etic de Investigació Clínica) of 
The Hospital Universitari Josep Trueta, in order to be evaluated and accepted. 
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6. LIMITATIONS OF THE STUDY 
The main limitation we have in the research we propose is confusing bias. The own 
characteristics of the pregnant women and previous medical history could have 
confounding effects on the study results and become conflicting. For this reason, we have 
collected as much co variables as possible that could skew the main variables we want to 
make the association (levels of PAPP-A, βhCG and ethnicity). These co variables are 
collected systematically by Obstetrics in the first trimester aneuploidy screening so as to 
calculate the risk. Poisson regression will include all co variables in order to adjust the 
Relative Risk as much as possible to our main variables.  
Another limitation of the study is the difficulty of the categorization of ethnicity by the 
clinician. The group “Others” comprises a wide variety of interpretations and results can be 
slanted as the measure of this variable is not accurate enough. Moreover, if we find 
differences between ethnicities, it could be not only for this but also for the place inhabited, 
the quantity or quality of nourishment, socioeconomic status, etc. 
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7. STUDY CHRONOGRAM
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ACTIVITY DEPENDANT 
1. Setting up 
All the Research Team of Gyn. and Obstetrics 
Department of the Hospital and Principal Project 
Investigators 
2,7,14,18. In person PI meetings Principal Project Investigators 
3. Literature review All research team 
4. Study research and proposal design Principal project investigators  
5. Analytical framework Principal Project Investigators 
6. Study research proposal evaluation CEIC (Comitè d’Ètica i Investigació Clínica) 
8. Data collection. Consecutive sampling 
All Gyneacologists team when women attend to first 
trimester screening and in chillbirth. 
9.  Computer processing data 
All Gyneacologists team when women attend to first 
trimester screening and in chillbirth. 
10. Evaluation of correct data collection Head of Gyneacology and Obstetrics Department 
11. Selection of exposed/Non exposed cases in 
Database Lifecycle 
Principal project investigators 
12. Selection of IUGR/non IUGR in SAP Gui for 
Windows Database 
Principal project investigators 
13. Descriptive population analysis.  Principal project investigators 
15.Statistical data analysis  Statistician 
16. Inspection of statistical analysis Head of Gyneacology and Obstetrics Department 
17. Final analysis of data Statistician 
19. Analysis of results All research team 
20. Discussion All research team 
21. Conclusion All research team 
22.  Article publication Publication Department 
23. Presentation to SEGO (Soc. Española de 
Ginecología y Obstetricia) and National 
Congresses 
All research team 
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8. BUDGET 
ITEM QUANTITY COST (€) TOTAL 
Literature review. Library 
expenses: 
- Payment articles and 
other literature material 
 
 
 
10units 
 
 
30€ 
 
 
300€ 
Staff working 
- Hire a Statistical Expert 
for data analysis 
 
1person/ 
30hours 
 
35€/h 
 
1050€ 
Material expenses 
- Printing and paper packs 
 
5u 
 
20€ 
 
100€ 
Publication costs 
- International journal of 
Gyneacology and Obstetrics 
 
-- 
 
3000€ 
 
3000€ 
Presentation costs 
- Presentation to SEGO 
- Presentation to a National 
Professional Congress 
 
-- 
-- 
 
1500€ 
1500€ 
 
1500€ 
1500€ 
Meeting-travelling expenses 
- Transport (AVE Bcn-
Madrid) 
- Accommodation 
- Food and miscellanea 
 
4 people 
 
4 people 
4 people 
 
≈85,50€ 
 
≈60€ 
≈ 100€ 
 
 
≈342€ 
 
≈240€ 
≈400€ 
TOTAL -- -- 8432 € 
 
 23 
 
9. CLINICAL AND HEALTHCARE IMPACT 
With this project we wish to achieve more information about the possible further values of the two 
biomarkers PAPP-A and βhCG, which nowadays are primarily used in the first trimester screening, 
together with the nuchal translucency (NT),  for the assessment of chromosomal abnormalities. Finding 
a new application for these markers would be only beneficial as they are performed by routine to all 
pregnant women. 
We would like to know if these markers in association with maternal ethnicity feature can help 
identifying women at risk of Intrauterine Growth Restriction. If the results show an association with a 
high predictability it would be reasonable to consider the possibility to perform increased surveillance 
for these high risk pregnancies, or maybe offer treatment interventions in early pregnancy, if more 
research is done in this field.  We also believe that if this work is published in SEGO (Soc. Española de 
Ginecología y Obstetricia) and presented to several National Congresses it will provide information and 
inspiration for further studies. If we manage to identify this condition in early pregnancy many more 
studies would like to invest about possible curative treatments from early weeks of gestation.  
Actually, this condition is the 2nd leading neonatal mortality and involves a large numbers of 
complications not only at short-term but also at long term. If we can follow more closely these patients 
we might reduce in the long term perinatal mortality and morbidity due to this adverse outcome. 
Besides, this would mean a reduction in the cost of length of stay in the Hospital, neonatal intensive 
unit and additional treatments.  
Finally, we hope this project will bring increased knowledge about mechanisms of Intrauterine Growth 
Restriction, since there is so little knowledge of its physiopathology.  
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10. TABLES, FIGURES AND PICTURES 
Picture I: Instituto Nacional de Estadística (www.ine.es). Prevalence of low birth weight in Spain.  
 
Picture II: DELFIA Xpress time-resolved fluoroimmunoassay (Perkin- Elmer, Turku, Finland) from 
Hospital Dr Josep Trueta Laboratory. 
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Picture III: The DELFIA Xpress assay is a solid phase two-site fluorometric assay based on the direct 
sandwich technique in which two monoclonal antibodies  (derived from mice) are directed against two 
separated antigenic determinants on the PAPP-A/ βhCG molecule. The DELFIA inducer dissociates 
europium ions from the labelled antibodies into the solution where they form highly fluorescent 
chelates and which is proportional to the concentration of PAPP-A  or β hCG (mU/L). 
  
 
 
Picture IV: LifeCycle database 3.2 for Prenatal Screening with Elipse Screening Engine from Hos pital 
Dr Josep Trueta Laboratory. 
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Picture V: Left: Spanish reference table abdominal perimeter by gestational age used in Hospital 
Materno-Infantil Vall d’Hebron and in Hospital Dr Josep Trueta. Top right:  Measurement of Abdominal 
circumference by ultrasound in Hospital Dr Josep Trueta. Bottom right: Estimated fetal weight is 
calculated automatically by the “Calculadora gestacional” v2013.1 from Francesc Figueras system.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Circunferencia Abdominal (CA) 
Semana P5 
(mm) 
P50 
(mm) 
P95 
(mm) 
16 85 95 105 
17 96 107 118 
18 108 118 128 
19 118 130 142 
20 128 141 154 
21 134 152 165 
22 150 164 178 
23 160 175 190 
24 170 187 204 
25 181 199 217 
26 192 211 230 
27 202 222 242 
28 212 233 254 
29 228 245 262 
30 236 254 272 
31 246 264 282 
32 254 274 294 
33 262 282 302 
34 270 292 314 
35 280 302 324 
36 288 310 332 
37 296 318 340 
38 302 326 350 
39 308 332 356 
40 310 336 362 
41 314 340 366 
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Picture VI: Left: Spanish reference table pulsatility index of umbilical artery used in Hospital Materno-
Infantil Vall d’Hebron and in Hospital Dr Josep Trueta (Arduini D J Perinat Med 1990; 18:165). Right: 
Doppler ultrasound of umbilical artery. 
 
 
 
 
Picture VII: Santamaría R. Spanish neonatal weight tables according to gestational age. En: S.A.M, ed 
1998. Used in Hospital Materno-infantil Vall d’Hebrón and in Hospital Dr Josep Trueta. 
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Table I: Baseline characteristics of the study population 
 Characteristics n=  % 
   Mean maternal age (years) 
 
__ 
Mean maternal weight (kg) 
 
__ 
Mean CRL at ultrasound (mm) 
 
__ 
Mean bHCG level  
 
__ 
Mean PAPP-A level 
 
__ 
Maternal ethnicity     
 Caucasian 
  
 Maghreb 
  
 Asiatic 
  
 Black african 
  
 Other 
  
Maternal smoking     
Maternal diabetes     
Mean birthweight (gr)     
IUGR fetuses     
 
Table 2: Low PAPP-A as predictive of IUGR by ethnicity 
PAPP-A as predictive of IUGR  
    
Variable   IUGR Non- IUGR RR (95% CI) p value 
      Caucasian PAPP-A <5th p         
 
PAPP-A <10th p         
 
PAPP-A >10th p     Reference __ 
      Asiatic PAPP-A <5th p         
 
PAPP-A <10th p         
 
PAPP-A >10th p     Reference __ 
      Maghreb PAPP-A <5th p         
 
PAPP-A <10th p         
 
PAPP-A >10th p     Reference __ 
      Black PAPP-A <5th p         
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Affrican 
 
PAPP-A <10th p         
 
PAPP-A >10th p     Reference __ 
      Other PAPP-A <5th p         
 
PAPP-A <10th p         
 
PAPP-A >10th p     Reference __ 
 
Table 3: Low β as predictive of IUGR by ethnicity 
βhCG as predictive of IUGR  
    
Variable   IUGR Non- IUGR RR (95% CI) p value 
      Caucasian βhCG <5th p         
 
βhCG <10th p         
 
βhCG >10th p     Reference __ 
      Asiatic βhCG <5th p         
 
βhCG <10th p         
 
βhCG >10th p     Reference __ 
      Maghreb βhCG <5th p         
 
βhCG <10th p         
 
βhCG >10th p     Reference __ 
      
Black African βhCG <5th p         
 
βhCG <10th p         
 
βhCG >10th p     Reference __ 
      Other βhCG <5th p         
 
βhCG <10th p         
 
βhCG >10th p     Reference __ 
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11. ANNEX 
Annex 1:  “Programa de diagnòstic prenatal d’anomalíes congènites fetals a Catalunya” 
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Annex 2: First trimester screening informed consent of Hospital Dr Josep Trueta 
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